

Chinese American Hematologist Oncologist Network (CAHON)

CAHON Reception/Meeting At the 2011 ASCO Annual Meeting

Timely News
and Information
Updates for
Members

Volume 2, Issue 2

May 1st, 2011

Dear Members and Colleagues:

We would like to extend a warm invitation for you to join in the CAHON reception held during the 2011 ASCO Annual Meeting at the following time and location:

**Saturday, 06/04/2011
6:30 PM-10:30 PM**

**Lao Beijing Restaurant
2138 South Archer Avenue
Chicago, IL 60616
(312) 881-0168**



RSVP to tianhong.li@ucdmc.ucdavis.edu, or weijing.sun@uphs.upenn.edu; or safiya.shabazz@uphs.upenn.edu

Your participation will strengthen the organization and promote dynamic interactions among members to achieve the delineated goals in our mission. We also welcome you to bring new fellow colleagues to join our growing CAHON. We will share the achievements of CAHON in the past year and plans for coming years. The final agenda will be available at the door, but we would highly appreciate your suggestions to tailor the draft agenda accordingly for a productive gathering.

We'd like to remind you that because of all the new regulations, we are unable to host this reception like we did during previous ASCO meetings. We need your support and energetic participation. Your general donation (tax-deductible) or out-of-pocket coverage of the service is highly appreciated. The estimated budget is about \$15-20/person with a bonus of enjoying a private gathering room.

Highlights:

- *Gathering Notice at the 2011 ASCO meeting*
- *Trials with NSABP*
- *Sino-US oncology meeting*
- *Abiraterone and ipilimumab approved and available for patient's care*
- *Academic exchange between China and USA*

NSABP: the Past, the Present and the Future

Based on the information from Dr. Janice Lu

The National Surgical Adjuvant Breast and Bowel Project (NSABP) is a not-for-profit clinical trials research group that is supported by the National Cancer Institute of the United States. For more than 40 years, the NSABP has been designing and conducting large-scale, randomized clinical trials in breast and colorectal cancers that have altered and improved that standard of care for men and women with these diseases.

Headquartered in Pittsburgh, Pennsylvania, NSABP has research sites at nearly 200 major medical centers, university hospitals and large oncology practice groups in the United States, Canada, Puerto Rico, Australia and most recently from Korea. More than 5000 physicians and nurses conduct NSABP trials at these centers.

NSABP researches have been the dominant force in altering the standard surgical treatment of breast cancer. It was the NSABP's breast cancer studies that led to the establishment of lumpectomy plus radiation over radical mastectomy as the standard surgical treatment for breast cancer. NSABP is also the first to demonstrate that adjuvant therapy could alter the natural history of breast cancer, increasing survival rates, and the first to demonstrate the preventive effects of Tamoxifen in breast cancer.

Since its beginning, the NSABP has randomized over 110,000 patients into adjuvant clinical trials in the breast and colon cancer, and another additional 13,000 women into the prevention trials. Recent Clinical trials are as follows:

NSABP FB-7 trial initiated in October of 2010. Protocol Chair: Janice Lu, MD PhD. It is a Phase II, multi-center randomized study of neratinib in combination with weekly paclitaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for women with HER2-positive locally advanced breast cancer. Patients in the control arm will receive neoadjuvant trastuzumab in combination with weekly paclitaxel followed by AC. The primary aim of the study is to determine the pathologic complete response (pCR) rate in breast and axillary nodes following the neoadjuvant therapy regimens. The secondary aims include determination of the pCR rate in breast only, clinical complete response (cCR) rate, two-year recurrence-free interval, two-year overall survival, toxicity of the neoadjuvant regimens, and exploration of molecular and genetic correlates of response. As the national protocol chair of this trial, we have recruited 24 US sites. We look forward to conducting this trial.

NSABP B47 trial is to start shortly. Protocol Chair: Louis Fehrenbacher, MD A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Normal Invasive Breast Cancer. The primary goal is to determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves invasive disease-free survival (IDFS) in women with resected node-positive or high-risk node-negative breast cancer which is HER2-negative by all HER2 testing performed. It is an innovative concept to use Trastuzumab in Her-2 normal amplified breast cancer.

Global diseases require global strategy

The Chairman of NSABP, Dr. Norman Wolmark, visited China and lectured at UICC Conference in ShenZhen in August of 2010. Although currently there are no members from China to join the NSABP, he is interested to have institutions in China to be a part of the NSABP. He believes that "global diseases require global strategy" and that "there are many opportunities to do trials together".

第二届《中美华人医师肿瘤学术论坛》

五月江南、生机勃勃，届时第二届《中美华人医师肿瘤学术论坛》暨"中美肿瘤协会成立大会"将于2011年5月13日-14日在中国苏州举行。

肿瘤是当今致死率最高的疾病，NCCN肿瘤临床实践指南是我们重要的参考指南，然而由于种族遗传学上的差异，东/西方人在对抗肿瘤药物的耐受性和肿瘤的敏感性方面存在较大的差异，美国华裔肿瘤专家和中国肿瘤专家对此差异进行了深入研究，并积累了丰富的临床经验。2009年4月于上海成功举办了首届《中美华人医师肿瘤学术论坛》，获得了高度评价和认同。本届学术论坛将秉承首届特色，邀请中美华人肿瘤学专家、国外学者就肿瘤临床医疗实践的经验和最新进展展开深入交流。本届论坛的主题为"中美华人肿瘤专家互相交流，共促华人肿瘤治疗的特色性发展"。主要讲演和讨论议题包括：1、肿瘤转化性研究专题；2、肺癌专题；3、乳腺癌专题；4、消化道肿瘤专题；5、淋巴浆细胞恶性肿瘤专题；6、姑息治疗及美国肿瘤治疗模式的探讨等，并在会议期间举行《中美肿瘤协会大会》。

全程参加论坛者，可获得国家I类医学继续教育学分6分。

组委会力求通过高质量学术演讲和互动的会议形式，构建一个供国内外肿瘤学专家、学者交流沟通的平台

会议基本信息：

主办单位：中美肿瘤协会（SACA, Sino-American Cancer Association）、上海交通大学医学院、上海交通大学医学院附属瑞金医院、上海交通大学医学院附属苏州九龙医院、上海市教委重点学科（肿瘤学）

承办单位：上海交通大学医学院附属苏州九龙医院

协办：上海交通大学医学院附属第三人民医院、《医学论坛报》、《中国医师论坛报》社、《24小时医学频道》、《肿瘤》杂志社、《Journal of Hematology & Oncology》

目标受众：会议面向中国的肿瘤专业人员、研究人员和研究生

执行主席 张凤春, David Zhang (美国)

The meeting news above appears belated, but may help our members to consider future participation, attendance, and/or to bring up new ideas to enhance exchanges between the two sides for better patient's care.

Several CAHON members will present at the meeting to support and affiliate the concept and affiliate the collaboration .

Two New Oncology Products Approved and Available to Patients

The two products, recently approved by the FDA, are ipilimumab injection (YERVOY[®]) for the treatment of unresectable or metastatic melanoma and abiraterone acetate (ZYTIGA) for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel, respectively. Please find more detailed prescribing information at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf for ipilimumab use or at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf for abiraterone acetate use.

Timely News and Information Updates

E-mail Addresses:

tianhong.li@ucdmc.ucdavis.edu

janice.lu@stonybrook.edu

ningy@mail.nih.gov

Weijing.Sun@uphs.upenn.edu

We are on Web:
<http://www.cahon.org/>

CAHON'S MISSION

CAHON, founded by Chinese American Hematologists and Oncologists in 2005, is dedicated to fostering communication amongst Chinese-American medical professionals for delivering high-quality health care to patients with neoplastic and hematological diseases, and to promoting medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a vital bridge between American and Chinese Hematology-Oncology communities in the levels of academia, industry, government regulation, and private practice.

Expand & Strengthen Academic Partnerships Between China and USA Medical Centers

To explore the possibility of new and expanded cooperating relationships with Chinese academic institutions, Stony Brook University President Samuel L. Stanley, Jr., M.D., and his wife, Ellen Li, M.D., Ph.D., traveled to China April 16 through April 23, 2011 with a Stony Brook University delegation (SBU) including William Arens, PhD, Tonja Johnson, PhD, Janice Lu, MD PhD, Deborah Klein, Yuefan Deng, PhD.

The Stony Brook University and China relationship was initiated shortly after the arrival of Nobel Laureate C.N. Yang in 1965 and solidified when Stony Brook benefactor and co-founder of Computer Associates International, Charles B. Wang, the Chinese Academy of Sciences and Stony Brook's College of Engineering and Applied Sciences.

The SBU group visited four of China's premier universities. In Beijing, the President renewed Stony Brook University's active and long standing student exchange agreements with Peking University and Tsinghua University. The president, with his delegation, also entered into talks regarding new cooperative academic programs with selected University-based Academic Medical Centers. The delegation also met with the executive body of the Chinese Language Council International, and sponsor of the Worldwide Confucius Institutes of which Stony Brook is a member.

After meeting with the President Wu Handong of Zhongnan University of Economics and Law (ZUEL) SBU's Confucius Institute partner in Wuhan, China, the SBU delegation continued on to Nanjing University to discuss expansion of Stony Brook University's Exchange and Dual Degree programs. Established in 2007, the Dual Degree program involves two years of study at NJU and two years of study at SBU.

We'd like to have more news contributions to enrich our news letter.

CAHON Management Team:

President: Weijing Sun, MD

VP: Yang-Min Ning, MD, PhD

Treasurer: Jeff Ye, MD

Chair, Membership: Tina Li, MD, PhD

Director, Education and Communication: Janice Lu, MD

Director, Clinic Practice Coordination: Zili He, MD

Director, Relationship and General management: Jingzhou Hou, MD

Adviser Board Chairman: Ruirong Yuan, MD, PhD